vs
Side-by-side financial comparison of Axalta Coating Systems Ltd. (AXTA) and Biogen (BIIB). Click either name above to swap in a different company.
Biogen is the larger business by last-quarter revenue ($2.5B vs $1.3B, roughly 2.0× Axalta Coating Systems Ltd.). Biogen runs the higher net margin — 12.9% vs 4.8%, a 8.1% gap on every dollar of revenue. On growth, Biogen posted the faster year-over-year revenue change (2.0% vs -3.7%). Biogen produced more free cash flow last quarter ($594.3M vs $286.0M). Over the past eight quarters, Biogen's revenue compounded faster (0.3% CAGR vs -1.2%).
Axalta Coating Systems Ltd., also known as simply Axalta, is an American company specializing in coatings in a wide variety of industrial applications, materials and sectors, including automotive paints. The company is based in Philadelphia, Pennsylvania, and incorporated in Bermuda. Axalta develops and manufactures coatings for light and commercial vehicles, industrial, and refinish applications. The firm does business in 130 countries, has nearly 13,000 employees, and has more than 100,000 ...
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
AXTA vs BIIB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.5B |
| Net Profit | $60.0M | $319.5M |
| Gross Margin | 33.4% | — |
| Operating Margin | 12.8% | — |
| Net Margin | 4.8% | 12.9% |
| Revenue YoY | -3.7% | 2.0% |
| Net Profit YoY | -56.2% | 32.8% |
| EPS (diluted) | $0.28 | $2.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.5B | ||
| Q4 25 | $1.3B | $2.3B | ||
| Q3 25 | $1.3B | $2.5B | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.3B | $2.4B | ||
| Q4 24 | $1.3B | $2.5B | ||
| Q3 24 | $1.3B | $2.5B | ||
| Q2 24 | $1.4B | $2.5B |
| Q1 26 | — | $319.5M | ||
| Q4 25 | $60.0M | $-48.9M | ||
| Q3 25 | $110.0M | $466.5M | ||
| Q2 25 | $109.0M | $634.8M | ||
| Q1 25 | $99.0M | $240.5M | ||
| Q4 24 | $137.0M | $266.7M | ||
| Q3 24 | $101.0M | $388.5M | ||
| Q2 24 | $112.0M | $583.6M |
| Q1 26 | — | — | ||
| Q4 25 | 33.4% | 78.3% | ||
| Q3 25 | 34.9% | 73.4% | ||
| Q2 25 | 35.0% | 77.1% | ||
| Q1 25 | 34.3% | 74.1% | ||
| Q4 24 | 34.1% | 76.2% | ||
| Q3 24 | 35.0% | 74.1% | ||
| Q2 24 | 34.0% | 77.8% |
| Q1 26 | — | — | ||
| Q4 25 | 12.8% | -2.5% | ||
| Q3 25 | 15.8% | 22.0% | ||
| Q2 25 | 14.8% | 28.1% | ||
| Q1 25 | 13.9% | 12.8% | ||
| Q4 24 | 14.3% | 11.9% | ||
| Q3 24 | 14.6% | 18.3% | ||
| Q2 24 | 15.2% | 28.3% |
| Q1 26 | — | 12.9% | ||
| Q4 25 | 4.8% | -2.1% | ||
| Q3 25 | 8.5% | 18.4% | ||
| Q2 25 | 8.4% | 24.0% | ||
| Q1 25 | 7.8% | 9.9% | ||
| Q4 24 | 10.5% | 10.9% | ||
| Q3 24 | 7.7% | 15.8% | ||
| Q2 24 | 8.3% | 23.7% |
| Q1 26 | — | $2.15 | ||
| Q4 25 | $0.28 | $-0.35 | ||
| Q3 25 | $0.51 | $3.17 | ||
| Q2 25 | $0.50 | $4.33 | ||
| Q1 25 | $0.45 | $1.64 | ||
| Q4 24 | $0.63 | $1.82 | ||
| Q3 24 | $0.46 | $2.66 | ||
| Q2 24 | $0.51 | $4.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $657.0M | $3.4B |
| Total DebtLower is stronger | $3.2B | — |
| Stockholders' EquityBook value | $2.3B | $18.7B |
| Total Assets | $7.6B | $29.5B |
| Debt / EquityLower = less leverage | 1.36× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $3.4B | ||
| Q4 25 | $657.0M | — | ||
| Q3 25 | $606.0M | — | ||
| Q2 25 | $625.0M | — | ||
| Q1 25 | $575.0M | — | ||
| Q4 24 | $593.0M | — | ||
| Q3 24 | $567.0M | — | ||
| Q2 24 | $840.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $3.2B | $6.3B | ||
| Q3 25 | $3.4B | $6.3B | ||
| Q2 25 | $3.4B | $6.3B | ||
| Q1 25 | $3.4B | $4.5B | ||
| Q4 24 | $3.4B | $6.3B | ||
| Q3 24 | $3.5B | $4.5B | ||
| Q2 24 | $3.6B | $6.3B |
| Q1 26 | — | $18.7B | ||
| Q4 25 | $2.3B | $18.3B | ||
| Q3 25 | $2.3B | $18.2B | ||
| Q2 25 | $2.3B | $17.6B | ||
| Q1 25 | $2.1B | $17.0B | ||
| Q4 24 | $1.9B | $16.7B | ||
| Q3 24 | $1.9B | $16.4B | ||
| Q2 24 | $1.8B | $15.9B |
| Q1 26 | — | $29.5B | ||
| Q4 25 | $7.6B | $29.4B | ||
| Q3 25 | $7.8B | $29.2B | ||
| Q2 25 | $7.8B | $28.3B | ||
| Q1 25 | $7.4B | $28.0B | ||
| Q4 24 | $7.2B | $28.0B | ||
| Q3 24 | $7.5B | $28.3B | ||
| Q2 24 | $7.3B | $26.8B |
| Q1 26 | — | — | ||
| Q4 25 | 1.36× | 0.34× | ||
| Q3 25 | 1.48× | 0.35× | ||
| Q2 25 | 1.50× | 0.36× | ||
| Q1 25 | 1.64× | 0.27× | ||
| Q4 24 | 1.78× | 0.38× | ||
| Q3 24 | 1.84× | 0.28× | ||
| Q2 24 | 2.02× | 0.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $344.0M | — |
| Free Cash FlowOCF − Capex | $286.0M | $594.3M |
| FCF MarginFCF / Revenue | 22.7% | 24.0% |
| Capex IntensityCapex / Revenue | 4.6% | — |
| Cash ConversionOCF / Net Profit | 5.73× | — |
| TTM Free Cash FlowTrailing 4 quarters | $453.0M | $2.4B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $344.0M | $511.9M | ||
| Q3 25 | $137.0M | $1.3B | ||
| Q2 25 | $142.0M | $160.9M | ||
| Q1 25 | $26.0M | $259.3M | ||
| Q4 24 | $234.0M | $760.9M | ||
| Q3 24 | $194.0M | $935.6M | ||
| Q2 24 | $114.0M | $625.8M |
| Q1 26 | — | $594.3M | ||
| Q4 25 | $286.0M | $468.0M | ||
| Q3 25 | $87.0M | $1.2B | ||
| Q2 25 | $97.0M | $134.3M | ||
| Q1 25 | $-17.0M | $222.2M | ||
| Q4 24 | $172.0M | $721.6M | ||
| Q3 24 | $161.0M | $900.6M | ||
| Q2 24 | $91.0M | $592.3M |
| Q1 26 | — | 24.0% | ||
| Q4 25 | 22.7% | 20.5% | ||
| Q3 25 | 6.8% | 48.4% | ||
| Q2 25 | 7.4% | 5.1% | ||
| Q1 25 | -1.3% | 9.1% | ||
| Q4 24 | 13.1% | 29.4% | ||
| Q3 24 | 12.2% | 36.5% | ||
| Q2 24 | 6.7% | 24.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | 1.9% | ||
| Q3 25 | 3.9% | 1.8% | ||
| Q2 25 | 3.4% | 1.0% | ||
| Q1 25 | 3.4% | 1.5% | ||
| Q4 24 | 4.7% | 1.6% | ||
| Q3 24 | 2.5% | 1.4% | ||
| Q2 24 | 1.7% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 5.73× | — | ||
| Q3 25 | 1.25× | 2.73× | ||
| Q2 25 | 1.30× | 0.25× | ||
| Q1 25 | 0.26× | 1.08× | ||
| Q4 24 | 1.71× | 2.85× | ||
| Q3 24 | 1.92× | 2.41× | ||
| Q2 24 | 1.02× | 1.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXTA
| Refinish | $509.0M | 40% |
| Light Vehicle | $372.0M | 29% |
| Industrial | $282.0M | 22% |
| Commercial Vehicle | $99.0M | 8% |
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
